Cipla is on track to launch key products, such as gAdvair, gAbraxane, gRevlimid and three peptide products over FY23-24, it said, adding that the US sales run-rate will improve from H2FY23, and barring COVID-19, sales performance in India continues to be robust. The brokerage firm expects a revenue CAGR of 13 per cent, an EBITDA CAGR of 21 per cent and a PAT CAGR of 28 per cent over FY22-24E.
Zerodha’s Nithin Kamath hails SCRA rule clarification for stock brokers, “huge” for Rainmatter. Here’s why
Nithin Kamath praised the Finance Ministry and NSE for clarifying SCRA rules, allowing brokers to invest their own funds freely. This regulatory shift will empower
June 10, 2025